Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation -95% Improvement Relative Risk Ventilation (b) -95% Hospitalization -41% Hospitalization (b) -17% Case -9% Case (b) -25% Case (c) -12% Case (d) -37% c19vitamind.com Jolliffe et al. NCT04579640 Vitamin D RCT Prophylaxis Favors vitamin D Favors control
Jolliffe, 4,464 patient vitamin D prophylaxis RCT: 41% higher hospitalization [p=0.16] and 9% more cases [p=0.55] https://c19p.org/jolliffe2
copied to clipboard
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
Jolliffe et al., BMJ, doi:10.1136/bmj-2022-071230 (date from earlier preprint), NCT04579640 (history)
23 Mar 2022    Source   PDF   Share   Tweet
RCT 5,979 low risk patients (0 COVID-19 deaths) in the UK, showing no significant differences with vitamin D prophylaxis. CORONAVIT. NCT04579640 (history). For more discussion see [reddit.com, twitter.com].
51% of confirmed COVID-19 cases were hospitalized in the control arm which is 7 times the median rate in other studies reporting both cases and hospitalization as of Sep 2022 (7.2%), suggesting possible issues with the data or major differences between the study population and the general population.
Authors do not provide exact start/end dates (month only) or specify when infections occurred, however based on cases in the UK, most infections may have been closer to the start of the trial when vitamin D levels may still have been relatively low. Reportedly, authors do not plan to analyze this issue, and have declined to allow one of the funders access to the data.
[Villasis-Keever] present an RCT showing conflicting results, 78% lower cases with vitamin D prophylaxis. In comparison, [Villasis-Keever] used a higher dose, the participants had much higher exposure to SARS-CoV-2 patients, and the study was prior to vaccination. In this study, 89% of participants had received a vaccine dose by the end of the study period, and the period overlapped with increasing solar UVB.
risk of mechanical ventilation, 94.7% higher, RR 1.95, p = 1.00, treatment 1 of 1,515 (0.1%), control 1 of 2,949 (0.0%), 3200IU/day.
risk of mechanical ventilation, 94.7% higher, RR 1.95, p = 1.00, treatment 1 of 1,515 (0.1%), control 1 of 2,949 (0.0%), 800IU/day.
risk of hospitalization, 41.1% higher, RR 1.41, p = 0.16, treatment 29 of 1,515 (1.9%), control 40 of 2,949 (1.4%), 3200IU/day.
risk of hospitalization, 16.8% higher, RR 1.17, p = 0.60, treatment 24 of 1,515 (1.6%), control 40 of 2,949 (1.4%), 800IU/day.
risk of case, 8.8% higher, RR 1.09, p = 0.55, treatment 76 of 1,515 (5.0%), control 136 of 2,949 (4.6%), 3200IU/day.
risk of case, 24.5% higher, RR 1.25, p = 0.11, treatment 87 of 1,515 (5.7%), control 136 of 2,949 (4.6%), 800IU/day.
risk of case, 12.3% higher, RR 1.12, p = 0.56, treatment 45 of 1,515 (3.0%), control 78 of 2,949 (2.6%), confirmed, 3200IU/day.
risk of case, 37.3% higher, RR 1.37, p = 0.08, treatment 55 of 1,515 (3.6%), control 78 of 2,949 (2.6%), confirmed, 800IU/day.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jolliffe et al., 23 Mar 2022, Randomized Controlled Trial, United Kingdom, peer-reviewed, median age 60.2, 24 authors, study period December 2020 - June 2021, dosage 3,200IU daily, daily, trial NCT04579640 (history).
Contact: d.a.jolliffe@qmul.ac.uk, a.martineau@qmul.ac.uk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit